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ABSTRACT Cellular recruitment during inflammatory/
immune responses is tightly regulated. The ability to
dampen inflammation is imperative for prevention of
chronic immune responses, as in asthma. Here we
investigated the ability of lipoxin A4 (LXA4) stable
analogs to regulate airway responses in two allergen-
driven models of inflammation. A 15-epi-LXA4 analog
(ATLa) and a 3-oxa-15-epi-LXA4 analog (ZK-994) pre-
vented excessive eosinophil and T lymphocyte accumu-
lation and activation after mice were sensitized and
aerosol-challenged with ovalbumin. At <0.5 mg/kg,
these LXA4 analogs reduced leukocyte trafficking into
the lung by >50% and to a greater extent than equiva-
lent doses of the CysLT1 receptor antagonist monte-
lukast. Distinct from montelukast, ATLa treatment led
to marked reductions in cysteinyl leukotrienes, interleu-
kin-4 (IL-4), and IL-10, and both ATLa and ZK-994
inhibited levels of IL-13. In cockroach allergen-induced
airway responses, both intraperitoneal and oral admin-
istration of ZK-994 significantly reduced parameters
of airway inflammation and hyper-responsiveness in a
dose-dependent manner. ZK-994 also significantly
changed the balance of Th1/Th2-specific cytokine lev-
els. Thus, the ATLa/LXA4 analog actions are distinct
from CysLT1 antagonism and potently block both
allergic airway inflammation and hyper-reactivity. More-
over, these results demonstrate these analogs’ thera-
peutic potential as new agonists for the resolution of
inflammation.—Levy, B. D., Lukacs, N. W., Berlin, A. A.,
Schmidt, B., Guilford, W. J., Serhan, C. N., Parkinson,
J. F. Lipoxin A4 stable analogs reduce allergic airway
responses via mechanisms distinct from CysLT1 receptor
antagonism. FASEB J. 21, 3877–3884 (2007)
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Airway inflammation in asthma is characterized by
mucosal infiltration of eosinophils (Eos) and T lympho-
cytes (Lymphs) and by elaboration of lipid and peptide
mediators that regulate the host inflammatory response
to inhaled allergens (1). Chronic anti-inflammatory
treatment is a principal tenet of current asthma man-
agement, yet corticosteroids, the main anti-inflamma-
tory modality in clinical use, can have deleterious
effects on normal physiological mechanisms of host
defense and homeostasis (1). In addition, 5% of
asthmatic patients are poorly controlled with cortico-
steroids and develop severe asthma that is refractory to
treatment (2). Moreover, no therapy is currently available
to modify asthma pathobiology and resolve the aberrant
immune activation. New approaches are needed.
A rapidly expanding number of counter-regulatory
mediators were recently uncovered that are endog-
enously generated to limit acute inflammatory re-
sponses and promote resolution (3). Lipoxins are the
first described endogenous lipid mediators of anti-
inflammation and resolution. Lipoxin A4 (LXA4) is a
short-acting, naturally occurring eicosanoid with potent
anti-inflammatory actions in vitro and in vivo (for a
recent review, see ref. 3). In humans, the lion’s share of
LXA4 is produced locally at sites of inflammation by
transcellular biosynthesis, and endogenous LXA4 syn-
thesis can be primed by cytokines. Aspirin, which is
known to inhibit prostaglandin and thromboxane bio-
synthesis, has a unique ability to trigger formation of
the 15-epimer of LXA4, both in vitro and in vivo, via a
mechanism involving cyclooxygenase-2 inhibition (3).
Aspirin-triggered lipoxins (ATLs) retain the anti-in-
flammatory properties of LXA4 and may mediate, in
part, aspirin’s therapeutic effects. LXA4 and the ATL or
15-epi-LXA4 exert anti-inflammatory effects through
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signals generated by binding to a high-affinity, G-
protein-coupled LXA4 receptor, denoted ALX. ALX
receptors are conserved in mammalian species and
constitutively expressed on neutrophils, Eos, mono-
cytes, and epithelium, thus being ideally localized to
play key roles in modulating cell-cell interactions and
cell-mediated immune responses in the airway. High-
level ALX expression on neutrophils and Eos correlates
with the ability of LXA4 to potently stop chemotaxis
and transcellular migration of these inflammatory cells.
Also of note, both LXA4 and 15-epi-LXA4 can compete
with leukotriene D4 (LTD4) for specific binding at
cysteinyl leukotriene 1 (CysLT1) receptors to serve in
vivo as an antagonist for CysLT signaling (4), similar to
existing asthma therapeutic agents, such as monte-
lukast (1).
Rapid metabolic inactivation of LXA4 and 15-epi-
LXA4 occurs via oxidation at C-15 and reduction at
C13-C14 (5). These LXA4 metabolites have a reduced
affinity for ALX and lower potency as anti-inflammatory
agents in vitro. Chemical modifications to the C15-C20
region of LXA4 and ATLs prevent metabolic inactiva-
tion, providing metabolically stable analogs with supe-
rior pharmaceutical characteristics (6). These analogs
have been used to establish that both LXA4 and ATLs
stop neutrophil diapedesis, reduce epithelial cell cyto-
kine release, and decrease vascular permeability of
murine skin exposed to inflammatory stimuli (3). Eos-
driven allergic reactions are also blocked by LXA4 and
its stable analogs (7, 8). In the airway, LXA4 and
specific LX analogs administered intravenously
dampen allergic airway inflammation and hyper-reac-
tivity (8), and promote resolution of mild acute lung
injury from aspiration of hydrochloric acid (9). Hence,
LXA4 serves as a selective agonist at ALX receptors for
cell type-specific actions and as an antagonist at CysLT1
receptors to block LTD4-mediated airway responses. Of
particular interest in asthma, glucocorticoids, the most
common anti-inflammatory agent used in its treatment,
can induce LX signaling circuits by increasing expres-
sion of leukocyte ALX receptors (10) and the counter-
regulatory peptide mediator annexin 1 that signals via
ALX (11). Taken together, these data indicate involve-
ment of the endogenous LXA4/ALX pathway in promot-
ing attenuation and/or resolution of responses to diverse
proinflammatory mediators in airway inflammation.
Here we provide new findings on the actions and
mechanisms for LXA4 analogs in altering allergic air-
way inflammation and hyper-reactivity in two distinct
murine models of allergen-driven asthmatic responses
and determine a structure activity relationship for
LXA4-specific actions in the airway that are distinct
from CysLT1 receptor antagonism.
MATERIALS AND METHODS
LXA4 analogs
The metabolically stable analog of the aspirin-triggered
15-epi-LXA4 methyl [5S,6R,7E,9E,11Z,13E,15S)-16-(4-flu-
orophenoxy)-5,6,15-trihydroxy-7,9,11,13-hexadecatetraenoate
(ATLa; see Fig. 1)] was prepared at Berlex using published
procedures (12). Material of 95% purity was qualified using
a synthetic LXA4 standard by
1H-NMR, HPLC coinjection
with photodiode array UV-visible detection (two methods),
and LC-MS-MS. HPLC analyses were carried out on a
LUNA 5  C18(2) column (2504.60 mm) using a gradi-
ent of methanol in water containing 0.1% acetic acid on a
Varian ProStar HPLC equipped with a diode array detec-
tor. The plasma half-life of ATLa after i.v. injection was
determined to be 15 min (13). The second-generation
analog, 5S,6R,7E,9E,13E,15S)-16-(4-fluorophenoxy)-3-oxa-
5,6,15-trihydroxy-7,9,13-hexadecatrien-11-ynoic acid (ZK-
994; see Fig. 1), was designed and prepared at Berlex to
block metabolism by -oxidation through insertion of a
3-oxa group and improve chemical stability through sub-
stitution of the tetraene group for a trienyne group (13).
The changes resulted in significant improvements in acid and
light stability, and an improved plasma half-life, but displayed
similar biological activity with a better pharmacokinetic pro-
file over ATLa (14, 15). The montelukast sodium was isolated
from Singulair tablets by extraction and chromatography at
Berlex Biosciences. Chemical and NMR analytical data were
consistent with the desired structure.
Ovalbumin sensitization and challenge
Five- to 7-wk-old male FVB (Charles River Laboratories,
Wilmington, MA, USA) mice were housed under pathogen-
free conditions. After Harvard Medical Area IRB approval
(protocol #03618), mice were sensitized with i.p. injections of
ovalbumin (OVA; Grade III, Sigma-Aldrich Co., St. Louis,
MO, USA) (200 g) plus 1 mg aluminum hydroxide (Sigma-
Aldrich) as adjuvant in 0.2 ml sterile saline (0.9%) on days 0
and 7. On days 14–17, mice received test compound (500
g/kg) by gavage, including 15-epi-16-parafluorophenoxy
LXA4-me (ATLa; 10 g22.8 nmol), 3-oxa-trienyne-16-
parafluorophenoxy LXA4 (3-oxa-LXA4; 10 g23.5 nmol),
montelukast (10 g16.4 nmol), or vehicle (0.5% ethanol)
in 0.2 ml sterile 0.9% saline 60 min before nebulization with
6% OVA (25 min). On day 18, mice were anesthetized and
underwent bronchoalveolar lavage (BAL) with two instilla-
tions of 1 ml PBS plus 0.6 mM EDTA. After inflation to 25 cm
H2O, lung tissues were excised into 10% neutral buffered
formalin (Fisher Scientific, Pittsburgh, PA, USA) for histolog-
ical examination.
Figure 1. Structure of LXA4 stable analogs. Structural analogs
of LXA4 were prepared to resist rapid conversion by PGDH
and -oxidation as well as -oxidation (ATLa) (see text for
further details). In addition, the tetraene was converted to a
trienyne to enhance chemical stability in light and acid
(3-oxa-LXA4).
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Cockroach allergen sensitization and induction
of airway responses
Five to seven week old Balb/c mice were immunized by i.p.
injection with 10 g of cockroach allergen (CRA, Bayer
Pharmaceuticals, West Haven, CT, USA) emulsified in incom-
plete Freund’s adjuvant on day 0. After 14 days the mice were
lightly anesthetized and given an intranasal challenge of 10
g of CRA in 10 l diluent to localize the response to the
airway. Seven days later animals were given an intratracheal
injection of 4 g of CRA in 40 l of sterile PBS or with PBS
alone (vehicle). A second intratracheal administration of
allergen was performed 48 h later. This procedure has
demonstrated a strong Th2-mediated, eosinophil-rich re-
sponse. Animals were treated with an LXA4 analog or vehicle
at the time of the final two intratracheal allergen challenges
or provided in the drinking water (0, 1, or 10 g/ml) for 3
days beginning on day 14, 2 h before intranasal allergen
challenge. The amount of water the animals consumed in the
3 day period of treatment was measured and averaged on a
per mouse basis. To conserve material, animals were analyzed
24 h after the final allergen challenge.
Allergen-initiated respiratory inflammation
BAL fluid was centrifuged (800 g, 10 min, 4°C), and the
supernatant was aliquotted and stored at 80°C for later
determination of mediator levels, including IL-4, IL-5, IL-10,
RANTES (R&D systems, Minneapolis, MN, USA), CysLTs
(Cayman Chemical, Ann Arbor, MI, USA), and LXA4 (Neo-
gen, Lexington, KY, USA). The cell pellet was gently resus-
pended in PBS for total cell counts. To determine differen-
tials, cells were concentrated onto microscope slides by
cytocentrifuge (STATspin, Norwood, MA, USA) (265 g) and
stained with a Wright-Giemsa stain (Sigma-Aldrich). At least
200 cells were counted per sample.
Lung homogenates
The right upper lobe from each mouse was flash-frozen in
liquid nitrogen and kept at 80°C. Just prior to running the
ELISA assays, the lungs were homogenized in 1 ml of homog-
enization buffer containing protease inhibitors (Complete,
Roche, Indianapolis, IN, USA) and 0.1% Triton-X 100 in PBS.
Lung cytokine and chemokine ELISAs
Cytokines were quantitated from homogenized lung aqueous
extracts using a double ligand ELISA system as in ref. 16.
Briefly, flat-bottomed 96-well microtiter plates were coated
with capture antibody (3.2 g/ml, overnight, 4°C). Nonspe-
cific binding sites were blocked with 2% BSA in PBS (1 h,
37°C). Plates were washed and specimens were added in
triplicate, followed by incubation at 37°C and washing. Bio-
tinylated antibody was added for 1 h at 37°C. After washing,
bound antibody was conjugated with streptavidin-peroxidase
and detected with chromogen substrate. The individual
polypeptides were standardized to total protein (ng/g total
protein). The lower limit of detection for these assays was50
pg/ml. These ELISAs are specific and do not cross-react to
other chemokine or cytokines.
Morphometric analysis of peribronchial Eos accumulation
Lungs from mice immunized and challenged with CRA or
vehicle were preserved with 4% paraformaldehyde (1 ml) on
day 18 postchallenge. The fixed lungs were embedded in
paraffin and multiple 50 m sections were stained with
Wright-Giemsa to identify Eos. Individual Eos were counted
from 100 high-power fields (HPF, 1000) per lung using
multiple-step sections of lung. The Eos counted were only in
the peribronchial region to ensure the enumeration of only
those Eos within or immediately adjacent to an airway. The
inflammation observed in this model was completely associ-
ated with the airway with little or no alveolitis.
Measurement of airway hyper-reactivity
Airway hyper-reactivity was measured using a Buxco mouse
plethysmograph specifically designed for low tidal volumes
(Buxco, Troy, NY, USA) as described (16). Briefly, the mice
were anesthetized, intubated, and ventilated with a Harvard
pump ventilator (tidal volume0.4 ml, frequency120
breaths/min, positive end-expiratory pressure 2.5–3.0 cm
H2O). Initial readings were acquired after 5 min of ventila-
tion. Once baseline levels were stabilized and initial readings
taken, a methacholine challenge was given via the cannulated
tail vein. After determining a dose response curve (0.001 to
0.5 mg), an optimal dose of methacholine (0.1 mg) was
chosen and used throughout the rest of the experiments in
this study. After methacholine challenge, peak airway resis-
tance was recorded as a measure of airway hyper-reactivity.
Statistical analyses
Numerical results were expressed as mean 	 se. Analysis of
variance was used to determine the level of difference be-
tween groups. Pairs of groups were compared by unpaired




LXA4 analogs differ from montelukast in regulating
key parameters of allergic airway responses to OVA
In a model of systemic allergen sensitization and airway
challenge, mice were sensitized to OVA and aerosol-
challenged on 4 successive days with 6% OVA in the
presence of 500 g/kg of either ATLa, ZK-994, or
montelukast, which were administered by gavage 60
min before aerosol challenge. Twenty-four hours after
the last of four daily OVA aerosol challenges, BAL was
performed or lung tissues were collected for micro-
scopic analyses (see Materials and Methods). Similar to
results with intravenous administration (8), ATLa was
bioavailable after enteric administration, leading to
significant reductions in BALF Eos and Lymphs (Fig.
2a, b). ZK-994 also significantly decreased both Eos and
Lymphs in BALF, but these decrements were substan-
tially less marked than with ATLa. Since only a single
dose was used, the differences in the regulation pattern
of mediators could be due to differences in the dose
response curves for the two analogs. Administration of
an equivalent amount of montelukast did not signifi-
cantly change the allergic airway inflammation in anti-
gen-sensitized and aerosol-challenged animals. ATLa
regulated lipid mediator levels, as both CysLTs and
endogenous LXA4 were decreased in these mice (Fig.
2c). ATLa also led to decreased Th2 cytokines IL-13,
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IL-4, and IL-5 as well as IL-10 in BAL fluids from
OVA-sensitized and challenged animals (Fig. 2d, e).
Inhibition appeared selective, since levels of RANTES
were not similarly reduced when determined in the
same samples of BAL fluid (Fig. 2d). ZK-994 gave a
significantly different pattern for regulation of media-
tors (Fig. 2c, d). Decrements in IL-13 and IL-4 were
observed with ZK-994, but the reductions were signifi-
cantly less than with ATLa (Fig. 2c, d). Of note, ZK-994,
unlike ATLa, led to higher levels of immunoreactive
LXA4 (Fig. 2c) and a marked inhibition of RANTES
(Fig. 2e). There was no significant change in CysLTs,
IL-5, or IL-10. Apart from inhibition of IL-13, these
findings with the LX analogs were in sharp contrast to
montelukast-treated mice, which displayed no signifi-
cant change in any of the other peptide or lipid
mediators, including CysLTs (Fig. 2c–e). These results
indicate that administration of LXA4 mimetics can
significantly inhibit allergic pulmonary inflammation,
including leukocyte infiltration and formation of spe-
cific mediators of interest in airway pathophysiology
such as key eicosanoids and cytokines. Differences in
actions between LX analogs and montelukast in BALF
leukocytes were also reflected in lung histopathology
(Fig. 3). Administration of ATLa, but not montelukast,
significantly reduced leukocyte infiltration, particularly
tissue Eos and Lymphs. Together, these findings indi-
cate that LXA4 regulates leukocyte trafficking in aller-
gic airway inflammation principally via ALX signaling
and not antagonism of CysLT1 receptors.
Oral ATLa treatment blocks airway responses to CRA
The cell population that has been most closely associ-
ated with asthma is the Eos (17) and, unlike the
Eos-rich alveolitis generated by OVA aerosol challenge,
direct airway challenge with CRA, a common clinical
trigger for human asthma (17), leads principally to
peribronchial Eos accumulation, which is required for
the development of airway hyper-reactivity (18). To
determine the effect of LXA4 on allergic airway re-
sponses in this second experimental model of asthma,
ATLa was prepared at two different concentrations, 1
g/ml H2O or 10 g/ml H2O, administered in the
animals’ drinking water just before intranasal CRA and
continued throughout the entire allergen challenge
period (see Materials and Methods). In the 3 days (72
h) of ATLa oral administration, the animals consumed
an average of 13 ml/mouse and 14 ml/mouse of the 1
and 10 g/ml, respectively; 24 h after the final allergen
challenge, the animals tested for airway hyper-reactivity
or lung tissues were processed for cytokine analysis. In
animals challenged with allergen and given ATLa orally
in the drinking water, airway hyper-reactivity to metha-
choline was significantly decreased in a dose-dependent
manner (Fig. 4a). The decreased airway responsiveness
Figure 2. LX stable analogs differ from montelukast in the regulation of
allergen-induced airway inflammation. BAL fluids were obtained from OVA-
sensitized and challenged mice that had been treated with500 mg/kg ATLa,
ZK994, or montelukast by gavage. a) Eos and b) Lymphs were enumerated and
identified after Wright-Giemsa stain. Results are expressed as means 	 se
(n6). c– e) Lipid mediators, cytokine and chemokine amounts in BAL fluids
from animals treated with vehicle, montelukast, or LX analogs were deter-
mined by sensitive and specific EIAs. Results are expressed as the mean 	 se
(n6, duplicate determinations). *P 
 0.05 by Student’s t test vs. vehicle
control, ‡P 
 0.01 vs. montelukast, and †P 
 0.03 vs. ATLa-treated animals.
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with ATLa was also associated with decrements in lung
IL-4 and IL-5 levels (Fig. 4b). Together, these findings
indicate that ATLa is orally active and that treatment
with ATLa potently regulates allergic airway responses.
ZK-994 decreases allergic airway responses to CRA
To determine whether the ZK-994 LX/ATL analog
could reduce CRA-driven airway inflammation, the
compound (100–1000 g/kg) or a vehicle control was
administered intraperitoneally 2 h before intratracheal
CRA challenge. Although the lowest dose of ZK-994
(100 g/kg) showed no significant effect on the devel-
opment of airway inflammation or hyper-reactivity (vide
infra), administration of ZK-994 at 400 g/kg and
higher led to reductions in airway responses. Lung
histology revealed reduced peribronchial inflammatory
infilitrates (Fig. 5a), and tissue morphometry demon-
strated significantly reduced peribronchial Eos accu-
mulation in those animals treated with ZK-994 (Fig. 5b).
In murine lung extracts, levels were determined for
select cytokines, including IL-4, IL-5, IL-10, IL-12, and
IFN (Fig. 6a, b), and chemokines, including C10,
RANTES, eotaxin, and MCP-1 (Fig. 6c). In this experi-
mental model, the only cytokine levels that were
significantly altered by ZK-994 were pulmonary IL-5,
IFN, and IL-10 (Fig. 6a, b). Significant decrements in
all the chemokines except MCP-1 were also present
with ZK-994 (Fig. 6c). Decreased IL-5, IL-10, and che-
mokine levels with increased amounts of IFN indicate
a central regulatory effect of this analog on adaptive
immunity that, in addition to LXA4’s direct cellular
actions, served to reduce leukocyte activation and traf-
ficking. Besides these parameters of inflammation, sys-
temic administration of ZK-994 by i.p. injection gave a
concentration-dependent inhibition of airway hyper-
reactivity to methacholine (Fig. 7a). This protection
from airway hyper-responsiveness to methacholine was
also present when ZK-994 was administered by oral
gavage. This reduction in bronchial hyper-reactivity
was similar in potency to that observed with equiva-
lent doses of montelukast (Fig. 7b). Together, these
data indicate that ZK-994 carries potent counter-
regulatory properties that dampen allergic airway
responses; it is orally bioavailable, and either oral
administration or a single systemic administration of
Figure 3. Lung histopathology from montelukast and ATLa-
treated mice. Male FVB mice were sensitized and aerosol-
challenged with OVA in the absence (top row) or presence
of 500 g/kg of either montelukast (middle row) or
ATLa (bottom row). Representative (n3) lung tissue
sections were obtained from formalin-fixed, paraffin-em-
bedded lung tissue prepared and stained with H&E. Mag-
nifications, 16 (left) and 40 (right). Br, bronchus.
Figure 4. Oral ATLa stable analog reduces both airway
hyper-responsiveness and inflammation. Mice were sensitized
and challenged with CRA in the absence (white) or presence
of ATLa [1 g/ml (hatched) or 10 g/ml (black)] in the
drinking water. a) Airway reactivity was determined by metha-
choline-dependent change in lung resistance. Results are
expressed as mean 	 se (n5). b) Lungs were homogenized
and levels of peptide mediators in the aqueous extracts were
determined by sensitive and specific EIAs. Results are ex-
pressed as the mean	 se (n4, d2). *P
 0.05 by Student’s
t test vs. vehicle control.
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ZK-994 has protective biological effects that persist
for several days.
DISCUSSION
Asthmatic lungs are characterized by leukocyte accu-
mulation and hyper-reactive airway responses. Media-
tors that regulate both leukocyte activation and func-
tional responses of lung resident cells have the
potential to resolve the disordered milieu of asthmatic
lung and promote a return to homeostasis. Lipoxins
display such properties. For example, LXA4 carries
counter-regulatory actions that inhibit neutrophil, Eos,
dendritic cell, Th2 lymphocyte, and natural killer cell
activation, block airway epithelial cell cytokine release,
modulate cytokine-induced metalloprotease activity,
and stimulate macrophage clearance of apoptotic cells
(reviewed in ref. 3). We recently uncovered the multi-
pronged inhibition of airway hyper-responsiveness and
inflammation by intravenous ATLa in a murine model
of OVA-induced allergic airway responses (8). Animals
transgenic for CD11b-targeted human ALX receptor
expression were also protected, presumably by a height-
ened sensitivity to endogenous levels of LXA4, during
the inflammatory response of these mice. Here we
present a structure activity relationship for the protec-
tive actions of two LX analogs and the CysLT1 receptor
antagonist montelukast in two mechanistically distinct
experimental models of allergic airway responses.
Cysteinyl LTs are generated during allergic airway
inflammation and serve as potent bronchoconstrictors
(19). CysLT1 receptor activation has been associated
with chronic airway inflammation and airway remodel-
ing (20). Because LXA4 and select analogs can interact
with both ALX and CysLT1, we directly compared
responses of LXA4 stable analogs to montelukast, a
pharmacological CysLT1 receptor antagonist, in aller-
gen-induced airway inflammation. Unlike montelukast,
LXA4 stable analogs significantly decreased Eos and
Lymph trafficking as monitored by lung histology and
enumeration of cells in BAL fluids. Both montelukast
Figure 5. 3-Oxa, trienyne-containing LXA4 stable analog reduces airway inflammation induced by cockroach allergy. Mice were
sensitized and challenged with CRA in the absence (white) or presence (black) of ZK-994 (100–1000 g/kg, i.p.). a) Lung tissue
sections were obtained from formalin-fixed, paraffin-embedded lung tissue prepared and stained with H&E, and b)
peribronchial eosinophil accumulation was determined by morphometry (see Materials and Methods). Results are expressed as
mean 	 se (n6, d2), *P 
 0.05 by Student’s t test vs. vehicle control.
Figure 6. ZK-994 regulates cytokine and chemokine mediators of Th2 adaptive immune responses to CRA. Mice were sensitized
and challenged with CRA in the absence (white) or presence (black) of 3-oxa-LXA4. a–c) Lungs from animals receiving ZK-994
(1000 g/kg, i.p.) or vehicle control were homogenized and levels of peptide mediators in the aqueous extracts were
determined by sensitive and specific EIAs. Results are expressed as the mean 	 se (n6, d2), *P 
 0.05 by Student’s t test vs.
vehicle control.
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and LXA4 analogs reduced IL-13 levels, yet only the LX
analogs dampened IL-4 and IL-5 levels. Of interest,
ATLa also blocked CysLT levels. These findings indi-
cate that LXA4 stable analogs transduce their protective
effects via sites of action, such as ALX, that are distinct
from CysLT1. It is still possible that decrements in IL-13
levels relate in part to regulation of CysLT1 signaling,
but the LXA4 stable analogs were substantially more
potent regulators of acute inflammation than monte-
lukast.
In two different experimental models of asthma,
systemic administration of LXA4 analogs modulated
local immune responses, including Eos accumulation,
Th2 type cytokine levels, and airway hyper-reactivity.
The approach used to elicit inflammation and airway
hyper-reactivity can be a critical determinant of the
cells and mediators that are responsible for the allergic
responses in murine lung (21) as well as the lung
compartment involved (18). Systemic sensitization by
i.p. injection of OVA adsorbed to an adjuvant, followed
by OVA aerosol challenge, induces airway eosinophilia
and hyper-reactivity with increased levels of Th2 cyto-
kines and chemokines; however, mast cells and IgE are
not required for these responses. In contrast, direct
administration of allergen, such as CRA, without adjuvant
to the airway leads to mast cell-dependent responses (21)
and a more focused peribronchial eosinophilia that better
reflects the pathobiology of human asthma (18). Here,
ATLa and ZK-994 provided protection in both models.
LXs and LX analogs are potent regulators of adaptive
immunity, including dendritic and epithelial cell re-
sponses (22, 23), as well as cellular effectors of both
innate and adaptive immunity such as neutrophils,
macrophages, Eos, and Lymphs (8, 9, 23, 24).
Several potential links between LX signaling and
cytokines and chemokines in regulating cellular re-
sponses have been uncovered (25). Activation of ALX
in monocytes leads to phosphorylation of the chemo-
kine receptor CCR5 and attenuates cell responses to
select chemokines (26). In addition, HIV gp120 binds
to ALX and alters the expression and function of CCR5
and CxCR4, again suggesting that this activation event,
via ligation of ALX receptors, actively alters the chemo-
tactic potential of leukocytes (27). In the OVA chal-
lenge model, ATLa and ZK-994 both inhibited airway
Eos but utilized slightly different mechanisms. ATLa
led to decrements in CysLTs and IL-5 whereas ZK-994
reduced RANTES. Specific cytokines, such as IL-5, and
chemokines, including C10, eotaxin, and RANTES,
play crucial roles in recruiting Eos to the site of allergic
reactions (28). In the CRA model, ZK-994 significantly
decreased all of these peptide mediators. Lipoxins also
regulate structural cells in the airway (29) and inflam-
matory pain (30). Because inflammatory and neu-
ropeptide mediators have also been associated with
airway remodeling in asthma (28), LXA4 stable analog
alteration of the mediator phenotype within the lung
has the potential to prevent chronic damage and lessen
severity in asthma.
LXA4 is generated during human asthmatic re-
sponses (31). More severe variants of asthma, including
aspirin-exacerbated respiratory disease, are associated
with diminished lipoxin biosynthesis compared with
more mild asthma (32, 33). The relative conversion of
arachidonic acid to LXA4 vs. CysLTs correlates with
airflow obstruction (32), and administration of LXA4 to
asthmatic subjects challenged with LTC4 significantly
attenuates airway responsiveness (34). In conjunction
with results presented here in experimental murine
models of asthma, these findings indicate that endog-
enous LXA4 can counter asthmatic inflammation and
airway responses.
In summary, our results demonstrate that LXA4 analogs
administered by gavage, i.p. injection, or orally in drink-
ing water regulate allergic airway responses in two differ-
ent experimental models with a mode of therapeutic
immunomodulation that is distinct from the currently
clinically used montelukast. Thus, the potent counter-
regulatory actions of LXA4 stable analogs display prom-
ise as needed therapies for allergic airway diseases and
as a new therapeutic strategy in asthma.
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